A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

460

Enrollment

INDUSTRY

Sponsor class

Stopped Study did not meet primary endpoint

Conditions

Diabetic Macular Edema

Interventions

DRUG: KSI-301
DRUG: Aflibercept
OTHER: Sham Procedure

Sponsor

Kodiak Sciences Inc